The era of GLP-1 receptor agonists: costs versus benefits
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 RA offer significant metabolic benefits, particularly in patients with type 2 diabetes.
“Beyond weight loss, GLP-1 RA offer significant metabolic benefits, particularly in patients with type 2 diabetes.6,9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 39 · see citing works
Kamarajah, S. K., Gudiozzi, N., Findlay, J. M., Lee, M. J., Pinkney, T., & Markar, S. R. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103408 · Cited by 29 · see citing works
“7 However, more recently, glucagon-like peptide-1 receptor agonists (GLP-1 RA) have emerged as a new pharmacological intervention, 8,9 initially developed for T2DM but now transforming the management of obesity.”
Park, S. K., & Choi, J. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217586 · Cited by 13 · see citing works
“In-frequently, pancreatitis, gallbladder disease, renal impairment, and thyroid C-cell tumors can occur, requiring vigilant clinical monitoring [146].”
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2 · see citing works
What role will physiological resilience play in brown-white fat dynamic in obesity management?
Zayachkivska, O., Kovalchuk, I., Muzyka, I., & Savytska, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1691149 · Cited by 2 · see citing works
Abdallah, H., Khalil, M., Mahdi, L., Pietragalla, G., Faienza, M. F., Garruti, G., & Portincasa, P. (2026) · Nutrients · doi:10.3390/nu18142317 · Cited by 1 · see citing works
“These financial and reimbursement barriers contribute to substantial socioeconomic and international disparities in access, underscoring the need for pricing reforms and equitable reimbursement policies to maximize the population-level benefits of these therapies [277].”
Bosy‐Westphal, A., Enderle, J., Norman, K., & Müller, M. J. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70334 · Cited by 1 · see citing works
Narayan, K. M. V. (2026) · Diabetes Care · doi:10.2337/dci25-0116 · Cited by 1 · see citing works
Are new obesity medications fueling eating and body image disorders?
de Oliveira, J. E. D. A. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.01.004
Storz, M. A., Huber, R., & Seufert, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8319702
- Authors
- Endocrinology, T. L. D. &.
- Corresponding author
- The Lancet Diabetes & Endocrinology
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 13
- Issue
- 1
- Pages
- 1
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4405267348
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 6 · 2025: 4
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- GLP-1 receptor agonists, semaglutide, type 2 diabetes, obesity, cardiovascular disease, cardiovascular disease prevention, drug costs, drug approval, real-world evidence, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
